Key result
Type 1 cardiorenal syndrome after AMI stems from interrelated hemodynamic, neurohormonal, inflammatory, and metabolic pathways.
Answers are grounded in this paper and cite their sources.
AKI following AMI is a multifactorial manifestation of type 1 cardiorenal syndrome driven by hemodynamic, neurohormonal, inflammatory, and adipokine-mediated metabolic mechanisms, warranting comprehensive management beyond contrast nephropathy prevention.
Acute kidney injury (AKI) is recognized as an independent predictor of adverse outcomes in patients with acute myocardial infarction (AMI). Current concepts of its pathogenesis are largely confined to the model of contrastinduced nephropathy, whereas the contributions of hemodynamic, neurohormonal, inflammatory, and especially metabolic mechanisms remain insufficiently integrated. The aim of this review was to analyze and summarize current evidence from publications indexed in PubMed and the Russian Science Citation Index (RSCI), primarily published between 2019 and 2025, concerning the pathogenesis of AKI in the setting of AMI. Acute kidney injury following myocardial infarction represents a typical manifestation of type 1 cardiorenal syndrome, developing secondary to acute cardiac dysfunction. Its pathogenesis is multifactorial and involves four major interrelated mechanisms: hemodynamic (reduced cardiac output, venous congestion, and impaired renal blood flow autoregulation), neurohormonal (hyperactivation of the sympathetic nervous system and the renin–angiotensin–aldosterone system), inflammatory (low-grade systemic inflammation triggered by cardiomyocyte death), and metabolic (visceral adipose tissue dysfunction accompanied by altered adipokine secretion in abdominal obesity). Particular attention should be paid to abdominal obesity, which creates a distinct metabolic risk phenotype in which pro-inflammatory adipokines, including leptin, chemerin, and neutrophil gelatinase-associated lipocalin (NGAL), exacerbate renal injury, whereas adiponectin exerts protective effects. Thus, AKI in patients with AMI results from the synergistic interaction of hemodynamic stress, neurohormonal dysregulation, systemic inflammation, and metabolic disturbances. Preventive and therapeutic strategies should therefore be comprehensive, encompassing not only the minimization of nephrotoxic exposures but also early optimization of hemodynamics, control of inflammatory responses, and consideration of the patient's individual metabolic profile. Understanding these pathogenic mechanisms is important for both diagnosis and prognosis, as it may improve risk stratification of patients with acute myocardial infarction by incorporating not only conventional clinical risk factors but also biomarkers of adipose tissue dysfunction.
No takes yet. Share an insight, caveat, or question.
Осиков et al. (2026) conducted a review in Acute kidney injury in patients with acute myocardial infarction. Acute kidney injury in acute myocardial infarction represents type 1 cardiorenal syndrome driven by 4 interrelated mechanisms: hemodynamic, neurohormonal, inflammatory, and metabolic dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: